Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SESRBZF 70 EV-to-EBIT is 40.51 as of Aug. 23, 2026, which is 45% above its 10-year median of 28.03. GuruFocus rates SRBZF with a GF Score™ of 70/100 and a GF Value™ of $93.44. The stock has 4 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Stratec SE ranks worse than 81.05% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Stratec SE's Enterprise Value for the quarter that ended in Jun. 2026 was $863.1 Mil.
Stratec SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE EV-to-EBIT Related Terms
Stratec SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Stratec SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Stratec SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Stratec SE's EV-to-EBIT falls into.
Stratec SE's current Enterprise Value is $433.5 Mil.
Stratec SE's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (SRBZF) has a EV-to-EBIT of 40.51 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Stratec SE and its competitors. This is 45% above median its historical median of 28.03. Over the past decade, Stratec SE's EV-to-EBIT has ranged from 8.25 to 56.46. According to the industry distribution chart, Stratec SE ranks #385 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 81.1%.
Is Stratec SE's EV-to-EBIT too high?
Stratec SE's current EV-to-EBIT of 40.51 is 45% above median its 10-year median of 28.03. Over the past 10 years, this metric has ranged from a low of 8.25 to a high of 56.46. The Medical Devices & Instruments industry median EV-to-EBIT is 18.95. Stratec SE's value of 40.51 is 113.8% above this industry median. Based on the distribution chart, Stratec SE ranks #385 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stratec SE has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #385 out of 475 companies for EV-to-EBIT. This places Stratec SE in the lower half of its industry. The industry median EV-to-EBIT is 18.95. Stratec SE's value of 40.51 is 113.8% above this benchmark. Historically, Stratec SE's own EV-to-EBIT has ranged from 8.25 to 56.46 over the past decade. While the company's 10-year median is 28.03 vs. the industry median of 18.95, Stratec SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.95, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stratec SE's current EV-to-EBIT of 40.51 is 113.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current EV-to-EBIT is 40.51, which is 45% above median its own 10-year median of 28.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Stratec SE (SRBZF) has a current EV-to-EBIT of 40.51. The stock's GF Value™ is $93.44, compared to a current price of $72.96 — trading 21.9% below its estimated fair value. The current EV-to-EBIT is 40.51, which is 45% above median its 10-year median of 28.03 and 113.8% above the Medical Devices & Instruments industry median of 18.95. Stratec SE's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Stratec SE (SRBZF), the current EV-to-EBIT is 40.51 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (SRBZF) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of $72.96 is trading 21.9% below its estimated GF Value™ of $93.44.
Key valuation signals for SRBZF:
EV-to-EBIT: 40.51 (45% above median its 10-year median of 28.03)
GF Value™: $93.44 vs. price of $72.96 (21.9% below fair value)
Industry Position: 113.8% above the Medical Devices & Instruments median (#385 of 475)
No single metric tells the full story. See the SRBZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
70GF Score
Get the complete analysis for SRBZF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRBZF has been successfully added to your 
